|
|
||||||||
Department of Molecular Genetics and Microbiology, Stony Brook University, Stony Brook, NY 11794
Members of the IFN regulatory factor (IRF) family regulate gene expression critical to immune response, hemopoiesis, and proliferation. Although related by homology at their N-terminal DNA-binding domain, they display individual functional properties. The distinct properties result from differences in regulated expression, response to activating signals, and interaction with DNA regulatory elements. IRF-3 is expressed ubiquitously and is activated by serine phosphorylation in response to viral infection or TLR signaling. Evidence indicates that the kinases TANK-binding kinase 1 and inhibitor of NF-
B kinase-
specifically phosphorylate and thereby activate IRF-3. We evaluated the contribution of another member of the IRF family, IRF-5, during viral infection since prior studies provided varied results. Analysis of phosphorylation, nuclear translocation, dimerization, binding to CREB-binding protein, recognition of DNA, and induction of gene expression were used comparatively with IRF-3 as a measure of IRF-5 activation. IRF-5 was not activated by viral infection; however, expression of TANK-binding kinase 1 or inhibitor of NF-
B kinase-
did provide clear activation of IRF-5. IRF-5 is therefore distinct in its activation profile from IRF-3. However, similar to the biological effects of IRF-3 activation, a constitutively active mutation of IRF-5 promoted apoptosis. The apoptosis was inhibited by expression of Bcl-xL but not a dominant-negative mutation of the Fas-associated death domain. These studies support the distinct activation profiles of IRF-3 in comparison to IRF-5, but reveal a potential shared biological effect.
This article has been cited by other articles:
![]() |
E. Wies, A. S. Hahn, K. Schmidt, C. Viebahn, N. Rohland, A. Lux, T. Schellhorn, A. Holzer, J. U. Jung, and F. Neipel The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5 J. Biol. Chem., March 27, 2009; 284(13): 8525 - 8538. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Y. Balkhi, K. A. Fitzgerald, and P. M. Pitha Functional Regulation of MyD88-Activated Interferon Regulatory Factor 5 by K63-Linked Polyubiquitination Mol. Cell. Biol., December 15, 2008; 28(24): 7296 - 7308. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Paun, J. T. Reinert, Z. Jiang, C. Medin, M. Y. Balkhi, K. A. Fitzgerald, and P. M. Pitha Functional Characterization of Murine Interferon Regulatory Factor 5 (IRF-5) and Its Role in the Innate Antiviral Response J. Biol. Chem., May 23, 2008; 283(21): 14295 - 14308. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Li, L. Tang, P. C. Roberts, J. M. Kraniak, A. L. Fridman, O. I. Kulaeva, O. S. Tehrani, and M. A. Tainsky Interferon Regulatory Factors IRF5 and IRF7 Inhibit Growth and Induce Senescence in Immortal Li-Fraumeni Fibroblasts Mol. Cancer Res., May 1, 2008; 6(5): 770 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Dideberg, G. Kristjansdottir, L. Milani, C. Libioulle, S. Sigurdsson, E. Louis, A.-C. Wiman, S. Vermeire, P. Rutgeerts, J. Belaiche, et al. An insertion deletion polymorphism in the Interferon Regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases Hum. Mol. Genet., December 15, 2007; 16(24): 3008 - 3016. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. J. Martin, J. M. Lee, D. Walls, and S. D. Hayward Manipulation of the Toll-Like Receptor 7 Signaling Pathway by Epstein-Barr Virus J. Virol., September 15, 2007; 81(18): 9748 - 9758. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Barro and J. T. Patton Rotavirus NSP1 Inhibits Expression of Type I Interferon by Antagonizing the Function of Interferon Regulatory Factors IRF3, IRF5, and IRF7 J. Virol., May 1, 2007; 81(9): 4473 - 4481. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yanai, H.-m. Chen, T. Inuzuka, S. Kondo, T. W. Mak, A. Takaoka, K. Honda, and T. Taniguchi Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression PNAS, February 27, 2007; 104(9): 3402 - 3407. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |